Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections

Phase 4 Unknown 100 enrolled Mahidol University

RandomizedParallel-groupOpen-labelTreatment

Summary

Adult patients with ESBL-producing Gram negative infections are randomized to receive ertapenem or meropenem/imipenem. Clinical and microbiological responses between both groups are compared.

Timeline

Start: 2011-05
Primary completion: 2013-04
Completion: 2013-08

Publications

Rattanaumpawan P, Werarak P, Jitmuang A, Kiratisin P, Thamlikitkul V. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial. BMC Infect Dis. 2017 Mar 1;17(1):183. doi: 10.1186/s12879-017-2284-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ertapenem	Small molecule	1 g	—
Comparator	IMIPENEM ANHYDROUS	Small molecule	0.5 g	—
Comparator	IMIPENEM ANHYDROUS	Small molecule	1 g	—
Comparator	Meropenem	Small molecule	0.5 g	—
Comparator	Meropenem	Small molecule	1 g	—

Indications

No indication recorded.